MajorDirect oral anticoagulants (factor Xa inhibitors)×Antiepileptics. Barbiturates
Updated · Methodology
Mechanism
CYP3A4/5 is the main enzyme that metabolises apixaban, and apixaban is a substrate of the transporter P-glycoprotein (P-gp) (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Phenobarbital has a strong enzyme-inducing effect: it induces cytochrome P450 enzymes and the transporter P-gp, so it lowers the levels and effect of many drugs (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The European apixaban SmPC lists phenobarbital among strong CYP3A4 and P-gp inducers. Such inducers can lower apixaban exposure by about 50%, and rifampicin reduced the apixaban area under the concentration–time curve (AUC) by 54% (EMA). The Spanish phenobarbital SmPC also names apixaban and warns of a possible loss of its effect (AEMPS).
Symptoms
The fall in apixaban levels causes no symptoms by itself. It shows as weaker protection against blood clots. According to the US apixaban label, this increases the risk of stroke and other thromboembolic events (apixaban label, US Food and Drug Administration, FDA). In a clinical study in people with atrial fibrillation, apixaban combined with strong inducers of the enzyme CYP3A4 and of P-glycoprotein showed lower efficacy and a higher risk of bleeding than apixaban alone (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). In the treatment of deep vein thrombosis and pulmonary embolism, the efficacy of apixaban with such inducers may be compromised (EMA).
Management
The US apixaban label says to avoid apixaban with combined P-glycoprotein (P-gp) and strong CYP3A4 inducers. Among them, it names rifampicin, carbamazepine, phenytoin and St John's wort (apixaban label, US Food and Drug Administration, FDA). Phenobarbital is not on this list, but the European apixaban summary of product characteristics (SmPC) classes it as such an inducer, and the Spanish phenobarbital SmPC describes it as an inducer of cytochrome P450 enzymes and P-gp (apixaban SmPC, European Medicines Agency, EMA; phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Do not use apixaban with phenobarbital to treat deep vein thrombosis or pulmonary embolism, because efficacy may be compromised (EMA). For three other indications, use apixaban with phenobarbital with caution and without an apixaban dose adjustment: prevention of stroke and systemic embolism in non-valvular atrial fibrillation, prevention of recurrent deep vein thrombosis and pulmonary embolism, and prevention of venous thromboembolism after elective hip or knee surgery (EMA). No clinical data are available in children who received apixaban with strong CYP3A4 and P-gp inducers (EMA). The Spanish phenobarbital SmPC names apixaban and warns of a possible loss of its effect but gives no specific measures for it (AEMPS). The documents do not say how long enzyme induction lasts after phenobarbital is stopped or when apixaban levels return to previous values.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Apixabán (nº registro 111691009), sección 4.4 (2026)– AEMPS, CIMA, nº registro 111691009, sección 4.4, texto de la EMA publicado en CIMA, consultado en septiembre de 2026
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- FDA: Eliquis (apixaban) prescribing information (2025)– FDA, DailyMed, Eliquis, E.R. Squibb & Sons, setid e9481622-7cc6-418a-acb6-c5450daae9b0, revisión 04/2025, secciones 4 y 7.1
- AEMPS: Ficha técnica: Fenobarbital (nº registro 35052), sección 4.5 (2025)– AEMPS, CIMA, nº registro 35052 (Luminal 100 mg comprimidos), revisión 07/2025 (texto de marzo de 2025), secciones 4.2, 4.4 y 4.5